Jenex signs Distribution Agreement for Australia and New Zealand.                                                                                                                                                                                 

Tuesday October 2, 2007.

BURLINGTON, Ontario--The Jenex Corporation (TSX Venture Exchange: JEN) (Frankfurt: JNX) (at Yahoo Finance, use JEN.V) announced it signed an exclusive agreement for the distribution of its Therapik® product that relieves the pain and itch of insect bites and stings.

Felton Grimwade & Bickford Pty Ltd (FGB) of Oakleigh South 3167, Australia will market Therapik in Australia and New Zealand.

The exclusive agreement between FGB and Jenex is for an initial five (5) year term and is subject to the successful completion of the required regulatory registration for Therapik prior to sale in Australia. FGB must meet certain volume purchasing requirements each year of the agreement to maintain their exclusivity in the territories.

Jenex President Michael Jenkins commented:  “We look forward to working with FGB as we continue to execute the commercialization phase of our business. We believe FGB’s market knowledge and experience in Australia and New Zealand will help us meet and exceed our sales targets for these markets.”

Mike McKelvie, CEO of FGB says: “We look forward to distributing Therapik® to our many markets as a device to eliminate the pain and discomfort of insect bites and stings. It is a product that every family should have.”

About Felton Grimwade & Bickford Pty Ltd:  FGB is an independent Australian owned and operated natural products company.

FGB manufactures and markets a range of essential oils, O.T.C. pharmaceuticals, nutritional supplements, household products, personal care products and medical devices in pharmacies and supermarkets throughout Australia, and in a growing number of export markets. (www.fgb.com.au)

About The Jenex Corporation: Jenex has a non-invasive Medical Device that prevents cold sore outbreaks .The interceptCS™ Cold Sore Prevention System is approved in Canada and has received CE approval for European Union countries.

In addition to interceptCS, Jenex markets Therapik® for insect stings & bites. It could be described as "Sting No More". It immediately relieves the pain & itch caused by stings & bites. Therapik is approved in Canada and the United States, as well as having CE Mark.

Jenex's Thermal Therapy is patented in the U.S., Canada, Australia, & Europe.

The company's Mission statement: "Inform and educate the public about our safe and effective products that have been clinically proven and approved to provide improved life style benefits." Vision statement: "Commercialization of our patented product line allowing Jenex to be the pre-eminent leader in cold sore prevention and insect bite & sting relief." Jenex has the potential to dominate two huge underdeveloped markets. Check www.interceptCS.com and www.JenexCorp.com for details.

The TSX Venture Exchange Inc. has not reviewed and does not accept responsibility for the accuracy or the contents of this press release. Certain information included in this press release is forward-looking and is subject to important risks and uncertainties. The results or events predicted in these statements may differ materially from actual results or events.

Contact:

The Jenex Corporation

Michael A. Jenkins, 905-632-3830

jenex@jenexcorp.com